GENITOURINARY CANCERS

REFERENCES

• SEER Cancer Statistics Review, http://Seer.cancer.gov/csr/1975_2004/ based on November 2006 SEER data submission, posted to the SEER web site, 2007
   Google Scholar
• Solsona E., et al. Effectiveness of single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: Short and long-term follow-up. J. Urol 1999; 161(4)1120–1123
   PubMed Web of Science ®Google Scholar
• Sylvester R., et al. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol. 2004; 171: 2186–219
   PubMed Web of Science ®Google Scholar
• Hendriks H., et al. EO9: A novel bioreductive alkylating Indoloquinone with preferential solid tumor activity and lack of bone marrow toxicity in preclinical models. Eur. J. Cancer 1993; 29A(6)897–906
   PubMed Web of Science ®Google Scholar
• Pardoll D. M. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2002; 2: 227–238
   PubMed Web of Science ®Google Scholar
• Borrello I., Pardoll D. GM-CSF-based cellular vaccines: A review of the clinical experience. Cytokine Growth Factor Rev. 2002; 13: 185–193
   PubMed Web of Science ®Google Scholar
• Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 1993; 90: 3539–3543
   PubMed Web of Science ®Google Scholar
• Simons J. W., Jaffee E. M., Weber C. E., Levitsky H. I., Nelson W. G., Carducci M. A., Lazenby A. J., Cohen L. K., Finn C. C., Clift S. M., Hauda K. M., Beck L. A., Leiferman K. M., Owens A. H., Jr., Piantadosi S., Dranoff G., Mulligan R. C., Pardoll D. M., Marshall F. F. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 1997; 57: 1537–1546
   PubMed Web of Science ®Google Scholar
• Simons J. W., Mikhak B., Chang J. F., DeMarzo A. M., Carducci M. A., Lim M., Weber C. E., Baccala A. A., Goemann M. A., Clift S. M., Ando D. G., Levitsky H. I., Cohen L. K., Sanda M. G., Mulligan R. C., Partin A. W., Carter H. B., Piantadosi S., Marshall F. F., Nelson W. G. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999; 59: 5160–5168
   PubMed Web of Science ®Google Scholar
• Simons J. W., Higano C., Corman J., Hudes G., Centeno A., Dula E., Smith C. M., Steidle C., Sacks N., Small E. J. A Phase I/II Trial of high dose allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. 2003; 22: 166, (Abstr.)
   Google Scholar
• Peehl D. The Male Reproductive System: Prostatic Cell Lines. Atlas of Human Tumor Cell Lines. Academic Press, Inc, NY 1995; 387–411
   Google Scholar
• Horoszewicz J. S., Kawinski E., Murphy G. P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987; 7: 927–935
   PubMed Web of Science ®Google Scholar
• Israeli R. S., Powell C. T., Corr J. G., Fair W. R., Heston W. D. Expression of the prostate-specific membrane antigen. Cancer Res. 1994; 54: 1807–1811
   PubMed Web of Science ®Google Scholar
• Lee W. H., Morton R. A., Epstein J. I., Brooks J. D., Campbell P. A., Bova G. S., Hsieh W. S., Isaacs W. B., Nelson W. G. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. U.S.A 1994; 91: 11733–11737
   PubMed Web of Science ®Google Scholar
• Simons J. W., Carducci M. A., Mikhak B., Lim M., Biedrzycki B., Borellini F., Clift S. M., Hege K. M., Ando D. G., Piantadosi S., Mulligan R., Nelson W. G. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin. Cancer Res. 2006; 12: 3394–3401
   PubMed Web of Science ®Google Scholar
• Drake C. G., Doody A. D., Mihalyo M. A., Huang C. T., Kelleher E., Ravi S., Hipkiss E. L., Flies D. B., Kennedy E. P., Long M., McGary P. W., Coryell L., Nelson W. G., Pardoll D. M., Adler A. J. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005; 7: 239–249
   PubMed Web of Science ®Google Scholar
• Berthold D., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study. Journal of Clinical Oncology 2007; 25(18S), abstract 5005
   Google Scholar
• Nelson J., et al. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3(2)110–116
   PubMed Web of Science ®Google Scholar
• Ryan C. J., Lin A. M., Small E. J. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol 2006; 24(3)250–253
   PubMed Web of Science ®Google Scholar
• Beer T. M., et al. High dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol 2006; 135(3)392–394
   PubMed Web of Science ®Google Scholar
• Beer T. M., et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J. Clin. Oncol. 2007; 25(6)669–674
   PubMed Web of Science ®Google Scholar
• Sternberg C., et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial. Journal of Clinical Oncology 2007; 25(18S), abstract 5019
   PubMedGoogle Scholar
• Gorem M. E., et al. Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment in an expanded access trial with subpopulation analysis. Proc. ASCO 2007; 237s, abst 5010
   Google Scholar
• Knox J., et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. Proc ASCO 2007; 237s, abst 5011
   Google Scholar